Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.44 0.15 −4.18%
Market cap
$14.5M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Latest quarter Q2 FY2026 · quarter to June 2026

Line Q2 FY26 On Q2 FY25 Against consensus
Revenue −$1.5M on Q2 FY25 n/m —
EPS, diluted $2.96 on Q2 FY25 n/m Missed by $1.50adjusted −$4.68 v −$3.18
Each line over the last 8 quarters
LineQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$123.0K$3.1M$2.7M$1.3M$1.1M$1.3M$3.7M−$1.5M
EPS, diluted−$4.25$4.50$1.15−$1.88$49.61−$3.51−$3.76$2.96

The consensus is analysts’ estimate of revenue and of adjusted EPS.

Revenue growth on a year earlier

Revenue grew -209% on a year earlier, against 37% the quarter before.

Revenue growth on a year earlier, by quarter
Q3 FY24−100%
Q4 FY24−88%
Q1 FY25−89%
Q2 FY2535%
Q3 FY25775%
Q4 FY25−59%
Q1 FY2636%
Q2 FY26−209%

Reports 16 Nov 2026 · Q3 FY26 · consensus EPS −$3.66

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 15
Revenue ttm 5
Net income ttm 183
Free cash flow ttm (38)
Net debt Q (91)
Valuation
P/E 0.1
Forward P/E FY26e n/m
Price / sales 3.1
Forward P/S FY26e Powerpack
Price / FCF n/m
Price / book n/m
Financial health
Current ratio Q 2.7 (at or above 1.5: strong)
Debt / equity Q n/m
Interest coverage Q (7.4)
Growth
Revenue growth FY26e −0.3% (below 0%: weak)
EPS growth FY26e −119.1% (below 0%: weak)
EPS growth FY27e −13.8% (below 0%: weak)
EPS growth, 5 yrs e +3.9%
Insiders
Net bought 12m 0
Sells 12m 0
Buys 12m 1
Owned by insiders 7.1%
Compound annual growth
10y 5y 3y
Sales (28.36%) (48.42%) (64.23%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation

P/S against its own 10 years 16.72%
10-year low 10-year high
EV/Sales against its own 10 years 67.79%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 183 131 213 257 176 235 141 47 30 6 5 (31.1%) 6 7 7 +3.8%
Gross margin, % 100.00 100.00 100.00 99.55 94.97 94.53 85.59 91.53 47.47 91.37 6.28 (8.6) pt
EBT (58) (121) (86) (77) (189) (291) (295) (323) (153) (58) (31) 0.0%
EBT margin, % (31.74) (92.03) (40.44) (29.87) (107.04) (123.53) (209.52) (690.60) (517.76) (905.19) (669.57) (873.4) pt
Net income (58) (121) (86) (77) (189) (290) (294) (284) (48) 183 183 n/m
Per share, $
Per share, $ Revenue 72.99 44.87 63.33 74.04 49.06 63.70 37.60 12.03 7.40 1.59 1.14 (34.6%)
Earnings (24.50) (43.25) (25.75) (22.25) (52.75) (78.50) (78.50) (73.00) (12.00) 45.37 45.30 n/m
Cash flow 2.83 (22.78) (22.65) (22.71) 22.70 (22.26) (38.99) (80.94) (34.48) (1.18) (9.40) n/m
Capex (0.50) (2.91) (2.33) (1.66) (1.11) (8.17) (10.35) (0.65) 0.19 (0.01) 0.00 (35.7%)
Free cash flow 2.33 (25.69) (24.98) (24.37) 21.59 (30.43) (49.33) (81.59) (34.29) (1.19) (9.40) n/m
Book value 69.77 187.61 157.17 154.50 122.82 62.02 (0.40) (47.19) (51.25) (4.21) (7.32) n/m
Shares, m 3 3 3 3 4 4 4 4 4 4 4 +5.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.08 0.0
P/S 7.30 28.25 18.27 14.48 18.90 5.53 10.61 0.55 1.79 5.51 3.10 11.1
P/B 7.63 6.76 7.36 6.94 7.55 5.68 0.00 0.00 0.00 0.00 0.00 4.2
EV/Sales 6.44 23.38 15.81 12.60 15.23 4.31 8.37 (0.26) 2.95 14.55 15.20 10.3
EV/FCF 201.61 (40.83) (40.08) (38.28) 34.60 (9.02) (6.38) 0.12 (0.64) (19.47) (1.84) 8.2
Cash, $m
Cash, $m Operating cash flow 7 (67) (76) (79) 82 (82) (146) (315) (138) (5) (38) n/m
Capex (1) (8) (8) (6) (4) (30) (39) (3) 1 0 0 (32.2%)
Free cash flow 6 (75) (84) (84) 78 (112) (185) (318) (137) (5) (38) n/m
Balance, $m
Balance, $m Working capital 201 663 601 600 592 249 219 114 63 70 61 (11.1%)
Net debt (156) (638) (513) (496) (661) (299) (325) (132) 23 (89) (91) (6.0%)
Shareholders’ equity 175 548 528 535 441 229 (1) (184) (205) (17) (30) n/m
Returns, %
Returns, % ROA (12.35) (17.67) (9.71) (8.86) (22.48) (36.24) (42.44) (55.00) (14.91) 109.81 131.26 +122.2 pt
ROIC (162.20) 0.00 (360.67) (142.19) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 +162.2 pt
ROE (31.22) (33.44) (16.06) (14.47) (38.76) (86.50) (258.01) 307.01 24.48 (165.18) (157.83) (134.0) pt
People
People Employees 364 423 461 531 599 566 592 486 225 34 — (23.2%)
Revenue/emp, $m 0.50 0.31 0.46 0.48 0.29 0.42 0.24 0.10 0.13 0.19 — (10.3%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

Kyntra Bio Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MRKR MARKER THERAPEUTICS, INC. $15.0M — (loss-making) — (loss-making) −51.00% (below 0%: shrinking) n/m −97.84% (below 0%: shrinking) 209.68% 0.00% Compare
JSPR Jasper Therapeutics, Inc. $14.8M — (loss-making) — — n/m +55.74% (above 0%: growing) 0.00% 0.00% Compare
CTXR Citius Pharmaceuticals, Inc. $14.6M — (loss-making) — — n/m −60.50% (below 0%: shrinking) 67.07% (785.39%) Compare
ADAPY Adaptimmune Therapeutics PLC $14.6M — (loss-making) — (loss-making) −89.33% (below 0%: shrinking) n/m −174.72% (below 0%: shrinking) 81.71% (221.45%) Compare
KYNB Kyntra Bio Inc $14.5M 0.1× — (loss-making) −209.35% (below 0%: shrinking) n/m −131.50% (below 0%: shrinking) 100.14% 1,192.27%
ALLR Allarity Therapeutics, Inc. $14.5M — (loss-making) — (loss-making) — n/m +15.63% (above 0%: growing) 100.00% (110,140.00%) Compare
NCEL NewcelX Ltd. $14.5M — (loss-making) — — — −87.71% (below 0%: shrinking) 0.00% — Compare
QNTM Quantum Biopharma Ltd. $14.4M — (loss-making) — (loss-making) — n/m +5.88% (above 0%: growing) 0.00% 0.00% Compare
MCRB Seres Therapeutics, Inc. $14.4M — (loss-making) — (loss-making) +68.95% (above 0%: growing) n/m −574.29% (below 0%: shrinking) 100.00% (2,723.78%) Compare
Median of peers $14.5M — — −51.00% — −74.10% 74.39% (221.45%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 27 April 2026

Ownership

Directors and executive officers, together 4.15%
Armistice Capital, LLC 9.35%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Kyntra Bio Inc (KYNB) Latest News

20 more headlines
All KYNB news, as stories →
stockrow.com/KYNB · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com